Loading...
OTC Markets
Totals
Securities
12,214
Dollar Vol
$2.7B
Share Vol
3.1B
Trades
358,241

OTC Markets Group uses cookies and similar technologies to help us understand how you use our websites, as further disclosed in our Privacy Policy. Our Terms of Service contain important information including restrictions on your use of our websites. By clicking “Accept”, or by continuing to use our websites, you consent to the use of cookies and agree to the terms of the OTC Markets Group Privacy Policy and Terms of Service.

ABTI
Alterola Biotech, Inc.

Common Stock
Alterola Biotech, Inc. Company Logo

47 Hamilton Square

Birkenhead Merseysid, ENG CH41 5AR

United Kingdom

Principal Executive Offices:

47 Hamilton Square

Birkenhead Merseysid, ENG CH41 5AR

United Kingdom

Last Verified 03/2022
Business Description
ALTEROLA BIOTECH INC. (OTC QB: ABTI) is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary product platform in a broad range of disease areas. The Company has a number of proprietary drug pipeline candidates including cannabinoids, cannabinoid-like molecules and non-cannabinoid molecules, which are under development for a range of indications. ABTI is also focused on producing quality, low cost of goods ingredients for the pharmaceutical, food and cosmetic sectors, from synthetic, biosynthetic and botanical sources. It is also focused on improving the drug delivery of such classes of compounds and has a range of proprietary ...
More
Financial Reporting
Reporting Status
U.S. Reporting: SEC Reporting
Audited Financials
Audited
Latest Report
CIK
0001442999
Fiscal Year End
3/30
Company Officers & Contacts
Timothy Paul Rogers
Acting CFO

Mr. Rogers has lived and worked extensively across the globe for over 30 years. An accountancy background, multi-lingual, with global experience in start-ups from Singapore, SE Asia, Australia, USA, Canada and Europe. He has significant experience in pharmaceuticals, agriculture, essential oils & cosmetics sectors and has strong European relationships with distributors.

Colin George Stott
COO

Mr Stott has a BSc (Hons) in Medicinal and Pharmaceutical Chemistry and is a veteran of the cannabis / cannabinoid medicines industry, with more than 20 years in the sector. As Director of Research and Development Operations at GW Pharmaceuticals, Colin was closely involved in the approval of Sativex, GW's first licensed cannabis-based product, and the more recently NDA-approved cannabinoid (CBD) medicine for treatment-resistant epilepsy, Epidiolex. He was also a key individual in the development of GW's discovery and development pipeline, until 2017. As Scientific Affairs Director, he was part of the Medical Affairs team responsible for the preparation for launch of Epidyolex in the international region (ex-US). Colin has more than 30 years' experience in preclinical & clinical development with specific expertise in the development of botanical medicines, particularly cannabinoid / cannabis-based medicines.

Board of Directors
Timothy Paul Rogers
Chairman, Compensation Committee Member, Nominating Committee Member

Mr. Rogers has lived and worked extensively across the globe for over 30 years. An accountancy background, multi-lingual, with global experience in start-ups from Singapore, SE Asia, Australia, USA, Canada and Europe. He has significant experience in pharmaceuticals, agriculture, essential oils & cosmetics sectors and has strong European relationships with distributors.

Daniel Reshef
Non-Executive Director, Independent Director

Dr Reshef is an experienced executive with a demonstrated history of strategic work in the pharmaceuticals industry. Skilled in Immuno-Oncology, Oncology, Biomarkers, Epidemiology, Vaccines, Ophthalmology, and Clinical Pharmacology. He is a Board certified MD (Ophthalmology). Strong clinical expertise and a healthcare services professional with a PhD in Epidemiology from Johns Hopkins University. A true leader with excellent communications skills and an appreciated manager with a long history of successful achievements in big programs.

Michael Hunter Land

Hunter Land has over 20 years of R&D expertise across 15 different indications, as well as 10 years of cannabinoid-focused research. As an expert in the field of cannabinoid science, he has developed a pipeline of discovery work on over 20 novel cannabinoids and terpenes. Previously, Hunter acted as the Sr. Scientific Director, Director of Cannabinoid Research, and scientific spokesperson at Canopy Growth Corporation. Most notably, Hunter co-established R&D for GW Pharmaceuticals within the US, where he co-authored multiple protocols in refractory epilepsy (Dravet Syndrome and Lennox-Gastaut Syndrome), Multiple Sclerosis, pain, and led the clinical development of Epidiolex (FDA approved prescription CBD). Hunter acts as the Sr. Scientific Advisor for the National Hockey League Alumni Association in conjunction with NEEKA Brain Health, a board member of Veterinary Cannabis Society, and lectures at the University of Wisconsin. He has been a featured speaker at over 50 scientific conferences, a named inventor on 6 patent applications, and has over 20 publications.

Seamus Henry McAuley

Mr. McAuley is a specialist in the commercial strategy, launch and growth of med-tech products and his experience spans a wide variety of sectors and therapeutic markets. A specialist in mergers and acquisitions, he brings a strong analytical, stakeholder management and leadership skills to proactively deliver new opportunities. A highly strategic leader, with an innate focus on innovation and future capability, Seamus demonstrates a proven capacity and successful results across the commercial environment through strong and focused leadership.

Dominic Christopher Schiller

Mr. Schiller is a qualified European Patent Attorney, and a specialist in intellectual property law within the cannabinoid pharmaceutical sector. He specializes in building patent portfolios for biotech companies. Most notably, he helped create and secure some of the earliest and most prominent cannabinoid related patents for GW Pharma, helping them establish an IP portfolio comprising claims directed to plants, plant extracts, extraction technology, pharmaceutical formulations, drug delivery and the therapeutic uses of cannabinoids, as well as plant variety rights. He has also served as patent attorney for a number of other pharma / biotech companies, securing patents relating to variety of botanically-derived and synthesized medicines, formulations and their medical use.. Mr. Schiller serves as Chief IP Officer to the Company.

Colin George Stott
Compensation Committee Member, Nominating Committee Member

Mr Stott has a BSc (Hons) in Medicinal and Pharmaceutical Chemistry and is a veteran of the cannabis / cannabinoid medicines industry, with more than 20 years in the sector. As Director of Research and Development Operations at GW Pharmaceuticals, Colin was closely involved in the approval of Sativex, GW's first licensed cannabis-based product, and the more recently NDA-approved cannabinoid (CBD) medicine for treatment-resistant epilepsy, Epidiolex. He was also a key individual in the development of GW's discovery and development pipeline, until 2017. As Scientific Affairs Director, he was part of the Medical Affairs team responsible for the preparation for launch of Epidyolex in the international region (ex-US). Colin has more than 30 years' experience in preclinical & clinical development with specific expertise in the development of botanical medicines, particularly cannabinoid / cannabis-based medicines.

Other Company Insiders

None

Other Company Insiders are all persons or entities beneficially owning 10% or more of any class of the issuer's securities. Together, officers, directors and other company insiders comprise Company Insiders.
Service Providers
Accounting/Auditing Firm
GreenGrowth CPAs

10250 Constellation Blvd.

Los Angeles, CA 90067

Securities Counsel
The Doney Law Firm

3651 Lindell Rd Ste D121

Las Vegas, NV 89103

Profile Data
SIC - Industry Classification
2833 - Medicinal and botanicals
Incorporation Information
NV, US, 2008
Employees
6 as of 03/23/2022
Shell
No
Products and Services

The Company is a pharmaceutical company which is undertaking research and development of prescription medicines containing, cannabinoid, cannabinoid-like and non-cannabinoid molecules. It is also developing biosynthetic methods / manufacturing capabilities for the biosynthetic production of cannabinoids. The Company intends to use these cannabinoid ingredients arising from this biosynthetic methodology to develop its own pipeline drug candidates. It also intends to sell the bulk cannabinoid ingredients into regulated sectors: namely the pharmaceutical, novel food / dietary supplement (in Europe) or cosmetic sectors.

Company Facilities

The Company does not own any properties or facilities of its own. The Company leases approximately 2,250 square feet of office space at 47 Hamilton Square, Birkenhead, Merseyside, CH41 5AR, United Kingdom. The office serves as the Head Office for the company.

Company Notes
Formerly=Jedediah Resources Corp. until 8-2010
Expert Market Icon
This market serves broker-dealer pricing and investor best execution needs. Quotations in Expert Market securities are restricted from public viewing.
Expert Market
Company is not current in its reporting obligations under Section 13 or 15(d) of the Exchange Act.
The company’s transfer agent has verified its outstanding shares directly to OTC Markets.
Daily Advancers
Subscribe to Our Newsletter
Stay up to date on the latest company news, industry trends and regulatory changes that affect our markets and learn about members of our community.